Abstract: A chimeric molecule that contains a fibrin-binding portion of an antibody covalently linked to an inhibitor of thrombin, which molecule is administered to inhibit thrombus formation and growth.
Type:
Grant
Filed:
May 3, 1993
Date of Patent:
August 22, 1995
Assignees:
President and Fellows of Harvard College, Emory University
Inventors:
Edgar Haber, Christoph Bode, Marschall S. Runge
Abstract: Four novel cell lines, ATCC #HB-8862 through ATCC #HB-8865 produce monoclonal antibody to human plasma prekallikrein. At least three of the antibodies also recognize plasma kallikrein, specifically the heavy chain thereof, and kallikrein-Cl-inhibitor complex; at least one of these three antibodies recognizes kallikrein-alpha.sub.2 -macroglobulin complex and kallikrein-antithrombin III complex. The antibodies do not cross-react with tissue kallikrein. The hybridomas are formed by fusing spleen cells from immunized BALB/c AnSkh mice with SP2/O-Agl4 myeloma cells. Diagnostic and biochemical uses of the monoclonal antibodies are provided.
Type:
Grant
Filed:
February 19, 1993
Date of Patent:
August 22, 1995
Assignee:
Temple University-of The Commonwealth System of Higher Education
Abstract: Novel fluorescent dyes based on the rhodol structure are provided. The new reagents contain functional groups capable of forming a stable fluorescent product with functional groups typically found in biomolecules or polymers including amines, phenols, thiols, acids, aldehydes and ketones. Reactive groups in the rhodol dyes include activated esters, isothiocyanates, amines, hydrazines, halides, acids, azides, maleimides, aldehydes, alcohols, acrylamides and haloacetamides. The products are detected by their absorbance or fluorescence properties. The spectral properties of the fluorescent dyes are sufficiently similar in wavelengths and intensity to fluorescein or rhodamine derivatives as to permit use of the same equipment. The dyes, however, show less spectral sensitivity to pH in the physiological range than does fluorescein, have higher solubility in non-polar solvents and have improved photostability and quantum yields.
Abstract: Apotransferrin bound to zinc or copper is administered to a patient who has endotoxins present in the patient's bloodstream. The apotransferrin improves the elimination of endotoxins from the bloodstream.
Abstract: There is provided a novel monoclonal antibody fragment which inhibits platelet function and may be useful in the treatment of thrombotic diseases. The fragment is produced by proteolytic digestion of the 7E3 monoclonal antibody.
Type:
Grant
Filed:
October 8, 1993
Date of Patent:
August 8, 1995
Assignee:
The Research Foundation of State University of New York
Abstract: cDNAs encoding a class of receptors, including the IL-8 type B receptor, have been identified in human tissue. Recombinantly produced IL-8 type B receptor is used in the preparation and purification of antibodies capable of binding to the receptor, and in diagnostic assays. The antibodies are advantageously used in the prevention and treatment of inflammatory conditions.
Type:
Grant
Filed:
February 25, 1994
Date of Patent:
August 8, 1995
Inventors:
Anan Chuntharapai, Caroline Hebert, Kyung J. Kim, James Lee
Abstract: The present invention provides novel DNA sequences, recombinant DNA (rDNA) molecules, processes for producing novel T-cell proteins expressed in T-cell development, the novel T-cell proteins in substantially pure form and antibodies which bind to the novel proteins. More particularly, it relates to novel DNA sequences expressed in appropriate hosts and the novel T-cell proteins produced in these hosts. The present invention also provides novel transmembrane proteins in substantially pure form, rDNA molecules encoding transmembrane proteins and processes for producing the novel transmembrane proteins.
Abstract: The invention is an isolated, sialylated glycoprotein, referred to as endosialin, which is expressed by tumor associated vascular endothelium and not normal vascular endothelium. The protein portion of the glycoprotein has a molecular weight of about 95 kilodaltons as determined by SDS-PAGE, and the glycoprotein has a molecular weight of about 165 kilodaltons, also as determined by SDS-PAGE. The oligosaccharides are linked by O-linkages to the protein. The glycoprotein is useful for making antibodies which are in turn used to identify tumor associated vascular endothelium.
Type:
Grant
Filed:
March 30, 1994
Date of Patent:
August 1, 1995
Assignee:
Memorial Sloan-Kettering Cancer Center
Inventors:
Pilar Garin-Chesa, Wolfgang J. Rettig, Lloyd J. Old
Abstract: The present invention provides a hybrid cell line producing monoclonal antibody to an acidic fibroblast growth factor (aFGF) protein. The hybridoma is established by fusing spleen cells from immunized mice with myeloma cells. The hybridomas are cultured as clones, and antibodies obtained from the individual clones are tested for their specificity for aFGF protein. Antibodies can be obtained from the culture growth medium or from ascitic fluid of mice bearing the hybridoma tumor. Diagnostic and therapeutic uses of the monoclonal antibody are also disclosed.
Type:
Grant
Filed:
March 4, 1993
Date of Patent:
August 1, 1995
Assignee:
Takeda Chemical Industries, Ltd.
Inventors:
Yuzo Ichimori, Koichi Kondo, Koichi Igarashi, Masaharu Sendo
Abstract: An antibody to septin, in which septin is an opsonin. Septin is isolated from human serum and is present at high levels in normal serum in distinction to the acute phase protein lipoprotein binding protein (LBP). Septin is an opsonin that is capable of binding to lipopolysaccharide to form a complex that is recognized by a receptor on monocytes, macrophage cells and polymorphonuclear cells, and that possesses an apparent molecular weight of about 90 kD as determined by SDS-PAGE analysis. Utilities of the antibody are provided, and testing procedures, materials in kit form, recombinant materials and procedures, and compositions are likewise set forth.
Abstract: A method for culturing mammalian hematopoietic stem cells is provided comprising maintaining a population of human stem cells in fixed, non-contacting relationship to a population of cultured stromal cells, which populations are in liquid stromal growth medium connection, so that the ability of the stem cells to differentiate and self-replicate is maintained during an extended culture period.
Type:
Grant
Filed:
April 3, 1992
Date of Patent:
July 25, 1995
Assignee:
Regents of the University of Minnesota
Inventors:
Philip B. McGlave, Catherine M. Verfaillie, Jeffrey S. Miller
Abstract: A monoclonal antibody is provided which is able to neutralize both human TNF .alpha. and TNF .beta., or a binding fragment thereof. A stable hybridoma cell line and progeny thereof are also provided which secrete such a monoclonal antibody. The monoclonal antibody or a fragment thereof may be used to detect the content of human TNF in a sample of body fluid.
Type:
Grant
Filed:
December 13, 1991
Date of Patent:
July 25, 1995
Assignee:
Farmitalia Carlo Erba S.R.L.
Inventors:
Elena Barbanti, Marta Ghislieri, Fabrizio Marcucci, Domenico Trizio
Abstract: A hybridoma (termed "UIC2 hybridoma", ATCC Accession No. HB11207) producing monoclonal antibodies (termed "UIC2 mAb") directed against an extracellular domain of a cell surface P-glycoprotein antigen associated with multidrug resistance in primate cells was produced by fusing a human myeloma cell with a spleen cell derived from a BALB/c mouse immunized with syngeneic 3T3 fibroblasts previously transfected with the isolated human mdr1 cDNA. UIC2 mAb, thus produced, as well as fragments and recombinant derivatives thereof, may be used to detect and isolate multidrug resistant primate cells and human mdr1 gene products, and to reverse multidrug resistance in primate cells, including cells of multidrug resistant human tumors.
Type:
Grant
Filed:
March 20, 1992
Date of Patent:
July 18, 1995
Assignee:
Board of Trustees of the University of Illinois
Abstract: Disclosed is a process for the preparation and use of gynecological tumor diagnostic and antitumor reagents. The process involves the pre-treatment of a patient with a viral oncolysate and the establishment of stable B cell human hybridomas capable of producing human monoclonal antibodies reactive with cell surface epitopes of human gynecological tumors. At least one such surface epitope is described as is the association constant of the antibody for certain gynecological tumor cells. Also disclosed are methods for utilizing the monoclonal antibodies of the invention in diagnoses and treatment of gynecological malignancies. In addition, two particularly useful gynecological hybridoma lines are disclosed which were derived from the process of the invention.
Type:
Grant
Filed:
June 18, 1992
Date of Patent:
July 18, 1995
Assignee:
Board of Regents, The University of Texas System
Inventors:
Ralph S. Freedman, Constantin G. Ioannides, Barbara J. Tomasovic, Rebecca S. Patenia
Abstract: Hair treatment compositions, hair damage protective agents and hair care products, each contain an active ingredient comprising an antibody which binds to human hair keratins which constitute intermediate-diameter filaments. This antibody can be produced efficiently and in a large quantities from the milk of a bovid animal immunized with said keratins. As this antibody binds to the hair specifically, it is effective in preventing the elution of proteins from the hair, imparting smoothness and flexibility to the hair, and improving the adaptability to combing and luster of the hair.
Abstract: A human monoclonal antibody, C5, specific for lipid A of the endotoxin core of Gram-negative bacteria and the hybridoma cell line which produces the antibody. The monoclonal antibody is produced by the fusion of lipid A sensitized lymphocytes and an appropriate fusion partner.
Type:
Grant
Filed:
August 25, 1993
Date of Patent:
June 20, 1995
Assignee:
The Board of Trustees of the Leland Stanford Junior University
Inventors:
Henry S. Kaplan, Abraham I. Braude, Nelson N. H. Teng
Abstract: A method of increasing the number of CD4+ cells in patients infected with the human immunodeficency virus is provided. The method includes injecting monoclonal antibodies directed against particular antigens on self-reactive, CD4 specific cytotoxic T-cells.
Abstract: A method of treating solid tumor cancer in a living being by prolonging the time a therapeutically effective agent remains in the tumor. The method comprises the steps of selecting particles of an aggregated protein and injecting them interstitially into the tumor. The therapeutically effective agent colloidal radioactive phosphorous is injected into the tumor either after the injection of the proteinaceous particles, or simultaneously.
Abstract: Disclosed are DNA sequences which encode an amino acid sequence homologous to a segment of Trichinella spiralis 53 kilodalton excretory-secretory antigen, recombinant polynucleotide molecules containing the sequences, and transfer and replication of the sequences in a transformed host to produce antigens useful as immunodiagnostic reagents or vaccines specific for T. spiralis.
Type:
Grant
Filed:
June 1, 1993
Date of Patent:
June 6, 1995
Assignee:
The United States of America as represented by the Secretary of Agriculture